How do I install the Endo Hirsutism Oc Initial Therapy Not Seeking Fertility skill?

Run npx skillmds@latest add dromlakhani/endo-hirsutism-oc-initial-therapy-not-seeking-fertility in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Which AI agents work with Endo Hirsutism Oc Initial Therapy Not Seeking Fertility?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Who published Endo Hirsutism Oc Initial Therapy Not Seeking Fertility?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Hirsutism Oc Initial Therapy Not Seeking Fertility by dromlakhani

Name: Endo Hirsutism Oc Initial Therapy Not Seeking Fertility
Rating: 4.666666666666667 (3 reviews)
Author: dromlakhani

Endo Hirsutism Oc Initial Therapy Not Seeking Fertility

Suggest oral combined estrogen–progestin contraceptives as initial therapy for most premenopausal women with patient‑important hirsutism who are not seeking fertility. Consider this approach when hirsutism persists despite cosmetic measures (shaving, plucking, waxing) and the patient desires pharmacological treatment.

dromlakhani Updated Sep 8, 2026 10 repo stars

File contents

Use oral contraceptives as initial therapy for most non‑fertility‑seeking women

STEP 1 — Gather Information

Record Ferriman–Gallwey score, assess whether hirsutism is patient‑important despite cosmetic measures, determine fertility desire, and collect medical history for venous thromboembolism (VTE) risk (age, BMI, smoking, hypertension, migraine with aura, personal/family VTE) and current medications.

STEP 2 — Rule In / Rule Out

If the patient is seeking pregnancy or planning conception → OC contraindicated; consider non‑estrogenic alternatives (e.g., antiandrogen with reliable contraception or direct hair removal). If not seeking fertility → proceed to assess OC safety.

STEP 3 — Classify or Stratify

Stratify VTE risk: low risk (age <39, BMI <30 kg/m², no smoking, no hypertension, no migraine with aura, no personal/family VTE) vs increased risk (any of: age ≥39, BMI ≥30, smoking, hypertension, migraine with aura, prior VTE, thrombophilia).

STEP 4 — Decide

Low risk: prescribe any combined OC containing ethinyl estradiol 20‑35 mcg and a progestin of patient choice. Increased risk: prescribe OC with ethinyl estradiol 20 mcg and a low‑risk progestin (e.g., norgestimate, gestodene, desogestrel) per Table 2. Schedule follow‑up in 3‑6 months to evaluate hirsutism improvement; if suboptimal after ≥6 months, add an antiandrogen.

Clinical Guardrails / Mimics / Pitfalls

Do not use OC in women seeking pregnancy, with active VTE, uncontrolled hypertension, migraine with aura, smoking >35 years, or known thrombophilia. Avoid antiandrogen monotherapy without reliable contraception. Do not rely on OC alone for rapid improvement in severe hirsutism; add antiandrogen only after ≥6 months of suboptimal response. Monitor blood pressure, weight, and mood during OC use.

Concrete Clinical Example

A 28‑year‑old woman presents with hirsutism (Ferriman–Gallwey 12) that is patient‑important despite daily shaving; she does not desire pregnancy, has BMI 22, no hypertension, no smoking, and no personal/family VTE. She is prescribed a combined OC with ethinyl estradiol 20 mcg and desogestrel. At 4‑month follow‑up she reports reduced hair growth and satisfaction; therapy is continued.

Source: Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-00241

---name: endo-hirsutism-oc-initial-therapy-not-seeking-fertilitydescription: Suggest oral combined estrogen–progestin contraceptives as initial therapy for most premenopausal women with patient‑important hirsutism who are not seeking fertility. Consider this approach when hirsutism persists despite cosmetic measures (shaving, plucking, waxing) and the patient desires pharmacological treatment.---# Use oral contraceptives as initial therapy for most non‑fertility‑seeking women## STEP 1 — Gather InformationRecord Ferriman–Gallwey score, assess whether hirsutism is patient‑important despite cosmetic measures, determine fertility desire, and collect medical history for venous thromboembolism (VTE) risk (age, BMI, smoking, hypertension, migraine with aura, personal/family VTE) and current medications.## STEP 2 — Rule In / Rule OutIf the patient is seeking pregnancy or planning conception → OC contraindicated; consider non‑estrogenic alternatives (e.g., antiandrogen with reliable contraception or direct hair removal). If not seeking fertility → proceed to assess OC safety.## STEP 3 — Classify or StratifyStratify VTE risk: low risk (age <39, BMI <30 kg/m², no smoking, no hypertension, no migraine with aura, no personal/family VTE) vs increased risk (any of: age ≥39, BMI ≥30, smoking, hypertension, migraine with aura, prior VTE, thrombophilia).## STEP 4 — DecideLow risk: prescribe any combined OC containing ethinyl estradiol 20‑35 mcg and a progestin of patient choice. Increased risk: prescribe OC with ethinyl estradiol 20 mcg and a low‑risk progestin (e.g., norgestimate, gestodene, desogestrel) per Table 2. Schedule follow‑up in 3‑6 months to evaluate hirsutism improvement; if suboptimal after ≥6 months, add an antiandrogen.## Clinical Guardrails / Mimics / PitfallsDo not use OC in women seeking pregnancy, with active VTE, uncontrolled hypertension, migraine with aura, smoking >35 years, or known thrombophilia. Avoid antiandrogen monotherapy without reliable contraception. Do not rely on OC alone for rapid improvement in severe hirsutism; add antiandrogen only after ≥6 months of suboptimal response. Monitor blood pressure, weight, and mood during OC use.## Concrete Clinical ExampleA 28‑year‑old woman presents with hirsutism (Ferriman–Gallwey 12) that is patient‑important despite daily shaving; she does not desire pregnancy, has BMI 22, no hypertension, no smoking, and no personal/family VTE. She is prescribed a combined OC with ethinyl estradiol 20 mcg and desogestrel. At 4‑month follow‑up she reports reduced hair growth and satisfaction; therapy is continued.**Source:** Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, doi:10.1210/jc.2018-00241

Frequently asked questions